Brian P Yaremko

List of Publications by Year
in descending order

21 papers	2,397 citations	1040056 9 h-index	794594 19 g-index
23 all docs	23 docs citations	23 times ranked	2886 citing authors

#	Article	IF	Citations
1	Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet, The, 2019, 393, 2051-2058.	13.7	1,333
2	Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. Journal of Clinical Oncology, 2020, 38, 2830-2838.	1.6	683
3	Stereotactic ablative radiotherapy for the comprehensive treatment of 4â€“10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer, 2019, 19, 816.	2.6	165
4	Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2019, 5, 681.	7.1	67
5	Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2019, 105, 943-947.	0.8	46
6	Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC). Radiation Oncology, 2017, 12, 30.	2.7	13
7	Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy. Gynecologic Oncology, 2019, 154, 183-188.	1.4	13
8	DCE-MRI assessment of response to neoadjuvant SABR in early stage breast cancer: Comparisons of single versus three fraction schemes and two different imaging time delays post-SABR. Clinical and Translational Radiation Oncology, 2020, 21, 25-31.	1.7	12
9	Assessment of tumour response after stereotactic ablative radiation therapy for lung cancer: A prospective quantitative hybrid 18 Fâ€fluorodeoxyglucoseâ€positron emission tomography and CT perfusion study. Journal of Medical Imaging and Radiation Oncology, 2019, 63, 94-101.	1.8	10
10	Cost Minimization Analysis of Hypofractionated Radiotherapy. Current Oncology, 2021, 28, 716-725.	2.2	9
11	An early report on outcomes from computed tomographic-based high-dose-rate brachytherapy for locally advanced cervix cancer: A single institution experience. Practical Radiation Oncology, 2011, 1, 173-181.	2.1	8
12	Intensity-Modulated Radiation Therapy Versus 3D Conformal Radiotherapy for Postoperative Gynecologic Cancer: Are They Covering the Same Planning Target Volume?. Cureus, 2016, 8, e467.	0.5	8
13	Reducing the dose of gadolinium-based contrast agents for DCE-MRI guided SBRT: The effects on inter and intra observer variability for preoperative target volume delineation in early stage breast cancer patients. Radiotherapy and Oncology, 2019, 131, 60-65.	0.6	7
14	Predicting pathological complete response (pCR) after stereotactic ablative radiation therapy (SABR) of lung cancer using quantitative dynamic [18F]FDG PET and CT perfusion: a prospective exploratory clinical study. Radiation Oncology, 2021, 16, 11.	2.7	7
15	A phase II trial to evaluate single-dose stereotactic body radiation therapy (SBRT) prior to surgery for early-stage breast carcinoma: SIGNAL (stereotactic image-guided neoadjuvant ablative radiation then) Tj ETQq1 1 0.784314 rgBT /Overlock	0.7	
16	Intrafraction motion monitoring to determine PTV margins in early stage breast cancer patients receiving neoadjuvant partial breast SABR. Radiotherapy and Oncology, 2021, 158, 276-284.	0.6	3
17	Dosimetry Study of [I-131] and [I-125]-Meta-Iodobenzyl Guanidine in a Simulating Model for Neuroblastoma Metastasis. Technology in Cancer Research and Treatment, 2013, 12, 79-90.	1.9	2
18	A Phase II Multi-institutional Clinical Trial Assessing Fractionated Simultaneous In-Field Boost Radiotherapy for Brain Oligometastases. Cureus, 2019, 11, e6394.	0.5	2

#	Article	IF	Citations
19	The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial () Tj ETQq1 1 0.784314 rgBT /Overlock 1	1.9	2
20	Assessment of function and quality of life in a phase II multi-institutional clinical trial of fractionated simultaneous in-field boost radiotherapy for patients with 1â€“3 metastases. Journal of Neuro-Oncology, 2016, 128, 431-436.	2.9	1
21	A Single Institution Consensus on the Use of Sequential or Concurrent Hormonal Therapy for Breast Cancer Patients Receiving Radiation Therapy. Cureus, 2016, 8, e555.	0.5	0